JP7570641B2 - 癌の処置又は予防において使用する為のキノリン誘導体 - Google Patents
癌の処置又は予防において使用する為のキノリン誘導体 Download PDFInfo
- Publication number
- JP7570641B2 JP7570641B2 JP2021535249A JP2021535249A JP7570641B2 JP 7570641 B2 JP7570641 B2 JP 7570641B2 JP 2021535249 A JP2021535249 A JP 2021535249A JP 2021535249 A JP2021535249 A JP 2021535249A JP 7570641 B2 JP7570641 B2 JP 7570641B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- formula
- compound
- pharma
- ceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306783.4A EP3669874A1 (en) | 2018-12-20 | 2018-12-20 | Quinoline derivatives for use in the treatment or prevention of cancer |
| EP18306783.4 | 2018-12-20 | ||
| PCT/EP2019/086470 WO2020127839A1 (en) | 2018-12-20 | 2019-12-19 | Quinoline derivatives for use in the treatment or prevention of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513517A JP2022513517A (ja) | 2022-02-08 |
| JP2022513517A5 JP2022513517A5 (cg-RX-API-DMAC10.html) | 2023-01-31 |
| JP7570641B2 true JP7570641B2 (ja) | 2024-10-22 |
Family
ID=65200518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535249A Active JP7570641B2 (ja) | 2018-12-20 | 2019-12-19 | 癌の処置又は予防において使用する為のキノリン誘導体 |
Country Status (11)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
| TW202436296A (zh) * | 2022-11-25 | 2024-09-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喹啉胺類化合物晶型及其製備方法 |
| WO2025027388A1 (en) | 2023-08-01 | 2025-02-06 | Abivax | Obefazimod for treatment of ulcerative colitis |
| IL326865A (en) * | 2023-08-30 | 2026-04-01 | Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd | Compound for regulating activity of microrna-124 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013545798A (ja) | 2010-12-15 | 2013-12-26 | スプリコス | Aidsを処置する為に有用な化合物 |
| JP2016505268A (ja) | 2013-01-17 | 2016-02-25 | アビバックス | バイオマーカーとしてのmiRNA−124 |
| JP2017032361A (ja) | 2015-07-30 | 2017-02-09 | 株式会社キーエンス | 画像検査装置、画像検査方法および画像検査プログラム |
| WO2017158201A1 (en) | 2016-03-18 | 2017-09-21 | Ratiopharm Gmbh | Process for preparing quinolin-2-yl-phenylamine derivatives and their salts |
| JP2018507215A (ja) | 2015-02-23 | 2018-03-15 | アビバックス | ウィルス感染の処置及び予防において使用する為の新規なキノリン誘導体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102625804B (zh) | 2009-06-12 | 2015-04-08 | Abivax公司 | 用于治疗aids的化合物 |
| CN103787992B (zh) * | 2014-01-21 | 2016-04-20 | 华东理工大学 | N,n-双取代苯并氮杂环-2-胺类化合物及其用途 |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
-
2018
- 2018-12-20 EP EP18306783.4A patent/EP3669874A1/en not_active Withdrawn
-
2019
- 2019-12-19 WO PCT/EP2019/086470 patent/WO2020127839A1/en not_active Ceased
- 2019-12-19 MA MA054512A patent/MA54512A/fr unknown
- 2019-12-19 MX MX2021007178A patent/MX2021007178A/es unknown
- 2019-12-19 CN CN201980088810.8A patent/CN113543784A/zh active Pending
- 2019-12-19 KR KR1020217022546A patent/KR20210136969A/ko not_active Ceased
- 2019-12-19 KR KR1020257024660A patent/KR20250117703A/ko active Pending
- 2019-12-19 EP EP19829187.4A patent/EP3897639A1/en active Pending
- 2019-12-19 CN CN202411117196.2A patent/CN118986981A/zh active Pending
- 2019-12-19 US US17/416,679 patent/US20220071985A1/en active Pending
- 2019-12-19 IL IL284124A patent/IL284124B2/en unknown
- 2019-12-19 BR BR112021012132-3A patent/BR112021012132A2/pt unknown
- 2019-12-19 AU AU2019408244A patent/AU2019408244B2/en active Active
- 2019-12-19 JP JP2021535249A patent/JP7570641B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013545798A (ja) | 2010-12-15 | 2013-12-26 | スプリコス | Aidsを処置する為に有用な化合物 |
| JP2016505268A (ja) | 2013-01-17 | 2016-02-25 | アビバックス | バイオマーカーとしてのmiRNA−124 |
| JP2018507215A (ja) | 2015-02-23 | 2018-03-15 | アビバックス | ウィルス感染の処置及び予防において使用する為の新規なキノリン誘導体 |
| JP2017032361A (ja) | 2015-07-30 | 2017-02-09 | 株式会社キーエンス | 画像検査装置、画像検査方法および画像検査プログラム |
| WO2017158201A1 (en) | 2016-03-18 | 2017-09-21 | Ratiopharm Gmbh | Process for preparing quinolin-2-yl-phenylamine derivatives and their salts |
Non-Patent Citations (1)
| Title |
|---|
| Bioorganic & Medicinal Chemistry Letters,2016年,26(14),pp.3307-3312 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3669874A1 (en) | 2020-06-24 |
| WO2020127839A1 (en) | 2020-06-25 |
| IL284124A (en) | 2021-08-31 |
| AU2019408244B2 (en) | 2025-03-20 |
| KR20210136969A (ko) | 2021-11-17 |
| CA3122912A1 (en) | 2020-06-25 |
| MA54512A (fr) | 2021-10-27 |
| US20220071985A1 (en) | 2022-03-10 |
| IL284124B1 (en) | 2025-03-01 |
| IL284124B2 (en) | 2025-07-01 |
| CN113543784A (zh) | 2021-10-22 |
| MX2021007178A (es) | 2021-07-07 |
| JP2022513517A (ja) | 2022-02-08 |
| CN118986981A (zh) | 2024-11-22 |
| BR112021012132A2 (pt) | 2021-09-08 |
| KR20250117703A (ko) | 2025-08-05 |
| EP3897639A1 (en) | 2021-10-27 |
| AU2019408244A1 (en) | 2021-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019408244B2 (en) | Quinoline derivatives for use in the treatment or prevention of cancer | |
| JP7762386B2 (ja) | 8-クロロ-n-(4-(トリフルオロメトキシ)フェニル)キノリン-2-アミンの非晶質固体分散物 | |
| EP2456441A1 (en) | Combination therapies with ck2 modulators | |
| JP2016521280A (ja) | 併用療法を用いて癌を治療する方法 | |
| RU2811417C2 (ru) | Производные хинолина для применения в лечении или предупреждении рака | |
| CA3122912C (en) | Quinoline derivatives for use in the treatment or prevention of cancer | |
| JP7823833B2 (ja) | 8-クロロ-n-(4-(トリフルオロメトキシ)フェニル)キノリン-2-アミンの共結晶及びその塩 | |
| BR122024023622A2 (pt) | Uso de um composto derivado de quinolina para tratamento ou prevenção de câncer | |
| TWI534148B (zh) | 吡唑並嘧啶前藥及其使用方法 | |
| HK40118235A (en) | Quinoline derivatives for use in the treatment or prevention of cancer | |
| WO2024263966A2 (en) | Compositions comprising antineoplastons and methods of treating pancreatic cancer | |
| WO2024263963A2 (en) | Compositions comprising antineoplastons and methods of treating head and neck cancer | |
| WO2024263804A2 (en) | Compositions comprising antineoplastons and methods of treating kidney cancer | |
| WO2024263972A2 (en) | Compositions comprising antineoplastons and methods of treating uncommon cancers | |
| EP4731792A2 (en) | Compositions comprising antineoplastons and methods of treating lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221228 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20230208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240314 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240613 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240731 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240911 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241001 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7570641 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |